Why the study?
Is QB-END/10 superior to VWF and UEA-1 as a marker of neoplastic vascular cells in malignant vascular tumours of the liver?
Is QB-END/10 superior to VWF and UEA-1 as a marker of neoplastic vascular cells in malignant vascular tumours of the liver?
QB-END/10 is a superior, more sensitive and specific marker for the differential diagnosis of malignant vascular tumours of the liver compared to VWF and UEA-1.
May aid pathologic distinction of hepatic vascular tumors; leaves open validation in larger diagnostic cohorts.
A new monoclonal antibody, QB-END/10, raised against the CD34 antigen in human endothelial cell membranes and haemopoietic progenitor cells, was studied for its usefulness as a marker of neoplastic vascular cells in 21 angiosarcomas and seven malignant haemangioendotheliomas of the liver. QB-END/10 was both more sensitive and more specific than Von Willebrand factor (VWF) and Ulex europaeus 1 agglutinin (UEA-1) in labelling endothelial cells and it did not cross react with epithelia as UEA-1 often does. Staining was uniformly strong and clear in all histological variants of these two tumours. QB-END/10 should prove particularly useful in the differential diagnosis of malignant vascular tumours of the liver.
No takes yet. Share an insight, caveat, or question.
Anthony et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: